New open access journal bridges basic and clinical research
Elsevier’s Cell Press and The Lancet form a new online journal: EBioMedicine
By Julie Stacey, PhD, and Duc Le, PhD Posted on 1 December 2014
The Ebola outbreak has claimed nearly 7,000 lives in West Africa, yet there exists no specific treatment or prevention except for patient isolation and palliative care. Despite advances in our understanding the lifecycle and pathogenicity of the virus, we have not yet identified clear molecular targets in these pathways which are amenable to antiviral drug and rational vaccine interventions. The World Health Organization (WHO) has agreed to the use of experimental drugs in Ebola patients as a last resort to curb the disease, while Ebola vaccine and drug candidates are currently being rushed through clinical trials.
This sobering example highlights the fact that the translation between insights into the mechanisms of disease and their prevention and treatment is not good enough. We have treatments for less than 10 percent of all known diseases that affect mankind, according to the National Center for Advancing Translational Sciences. Drug development is a time-consuming and costly process, and although we have a vast amount of data from cell and molecular biology, animal models and the advancement of "-omics" sciences – genomics, proteomics, metabolomics – transforming this knowledge into practical interventions to improve human health is a process with many hurdles.
These are examples of the types of translational needs that the journal EBioMedicine hopes to help solve – by serving as a multidisciplinary and public forum at the interface of scientific research and clinical application, and by publishing primary research articles aimed at translational approaches to solving major health-related threats. The overarching aim of the journal is conveyed by its slogan: "Translating science to improve health."
EBioMedicine is an Elsevier journal published with editorial support from Cell Press and The Lancet. It combines the rigor and visibility associated with Cell Press and The Lancet family of journals with the publishing experience of Elsevier, providing global availability via open access. Laboratory researchers, clinical practitioners and health policymakers can share their findings, comment on others' work, and collaborate to facilitate the translation of basic science into useful tools for human health improvement.
The scope of EBioMedicine spans the entire spectrum of basic biomedical and clinical research fields, including major areas such as cancer, neuroscience, cardiology, infectious disease, immunology, genetics, endocrinology & metabolism and rheumatology.
Given the direct relevance of EBioMedicine to the health and well-being of the general public, and our intent to be a forum for expediting cross-pollination of a broad range of scientific and clinical disciplines, we expect the journal to become a leader in the rapid and public communication of research advances. All research articles will be rigorously peer-reviewed and fast-tracked, bringing high-quality publications to the public as quickly as possible.
"We have entered an era where bench is at bedside, providing unprecedented opportunities to convert fundamental discoveries into clinical endpoints," said Dr. Ronald A DePinho, Professor and President of the University of Texas MD Anderson Cancer Center and a member of the journal's Advisory Board. "EBioMedicine seeks to foster integration across the worlds of basic and clinical research with the goal of improving human health."
Dr. Johanne Martel-Pelletier, Professor and Director of the Osteoarthritis Research Unit at the University of Montreal Hospital Research Centre, who also serves on EBioMedicine's Advisory Board, explained the importance of translational medicine and cross-functional collaboration:
From the perspective of personalized therapeutic management, one of the most pressing issues is to identify the patient population most susceptible to benefit from a treatment. This may be achieved with increasing translational medicine initiatives by promoting cross-functional collaborations between researchers and clinicians as well as the pharmaceutical industry.
Through the EBioMedicine platform, the editors will encourage discussion from authors, helping bring together the communities of researchers and physicians. The editors will also be actively engaged in Twitter and Mendeley groups to promote and share content.
The editors, together with Executive Publisher Dr. Andrea Hoogenkamp-O'Brien, will guide the journal and platform strategy and ensure that the needs of everyone engaged with accelerating the pipeline of translating research into improved human health are met. Ultimately, we hope the journal will develop into the primary destination where researchers, clinicians and health officials can meet and share their research and opinions and work together in finding new solutions for all our global health challenges.
Watch a video about EBioMedicine
Elsevier Connect Contributors
Dr. Julie Stacey received her BA in Biochemistry from Bowdoin College in Maine and completed her doctoral research in microbiology at Mount Sinai School of Medicine in New York City. She continued her post-doctoral studies at Rockefeller University in New York and then joined Cell Press in 2004, where she worked for more than 10 years as a scientific editor. Dr. Stacey joined EBioMedicineas the US Editor-in-Chief in 2014.
Dr. Duc Le graduated with a BSc in Applied Biology/Biotechnology from RMIT University in Melbourne, Australia, and worked as a researcher at the National Institute for Hygiene & Epidemiology in Vietnam. He received a PhD in Immunology from Royal Holloway University of London and completed a 3-year post-doctoral term there. He then worked at Future Science Group in the UK as Senior Editor for several journals and books. He joined Elsevier in 2014 as UK Editor-in-Chief for EBioMedicine.
Follow them via @EBioMedicine.